NMRA
NASDAQ · Pharmaceuticals
Neumora Therapeutics Inc
$2.51
-0.06 (-2.33%)
Open$2.55
Previous Close$2.57
Day High$2.63
Day Low$2.50
52W High$3.65
52W Low$0.61
Volume—
Avg Volume727.5K
Market Cap497.09M
P/E Ratio—
EPS$-1.46
SectorPharmaceuticals
Analyst Ratings
Strong Buy
15 analysts
Price Target
+590.8% upside
Current
$2.51
$2.51
Target
$17.34
$17.34
$11.85
$17.34 avg
$21.76
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 131.86M | 126.94M | 118.45M |
| Net Income | 20.35M | 17.55M | 19.05M |
| Profit Margin | 15.4% | 13.8% | 16.1% |
| EBITDA | 29.65M | 29.50M | 31.41M |
| Free Cash Flow | 15.46M | 12.66M | 10.19M |
| Rev Growth | -7.9% | +5.6% | -2.9% |
| Debt/Equity | 0.29 | 0.31 | 0.30 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |